ADXS News 2.67 04/22/2014 17:16:28 Advaxis Inc (ADXS)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Advaxis Inc (ADXS) 2.67 $ADXS

Japan Patent Office Issues Advaxis a Notice of Allowance for Two Patent Applications Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Mon Apr 14, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the Japan Patent Office issued to Advaxis two notices of allowance for two patent applications (P-72863-JP, P-7924) with claims for each patent application related to the Company's proprietary cancer immunotherapy platform technology. These patents will provide protection in Japan until 2030.

Pending Applications, Closed Public Offering, Joint Venture Formation, Executive Appointment, and Commercial Launch - Analyst Notes on Gilead, Enzymotec, Intrexon, Advaxis, and Repligen
PR Newswire - Tue Apr 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Enzymotec Ltd. (NASDAQ: ENZY), Intrexon Corporation (NYSE: XON), Advaxis, Inc. (NASDAQ: ADXS), and Repligen Corporation (NASDAQ: RGEN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Advaxis Receives Notice of Allowance From U.S. Patent and Trademark Office for Three Patent Applications With Multiple Claims Covering Its Cancer Immunotherapy Platform Technology
GlobeNewswire - Tue Apr 01, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for three U.S. patent applications (12/213,696, 13/254,607, and 11/415,271) with claims of each application related to the Company's proprietary cancer immunotherapy platform technology. The patent with the latest date of expiry is 2030, without taking into account patent term extension.

Advaxis Announces Closing of Public Offering of Common Stock
GlobeNewswire - Mon Mar 31, 3:37PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the closing of a previously announced underwritten public offering of 4,692,000 shares of its common stock, including the fully exercised over-allotment option by the underwriters covering 612,000 shares, offered at a price to the public of $3.00 per share. The gross proceeds to the Company were $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Moskowitz: Advaxis Balance Sheet Shored Up
ACCESSWIRE - Mon Mar 31, 8:40AM CDT
Read the Advaxis Report Update: http://equitiesiq.com/reports/advaxis-update/

Advaxis Announces Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Fri Mar 28, 2:00PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 612,000 shares of its common stock at a public offering price of $3.00 per share in connection with its previously announced underwritten public offering of 4,080,000 shares of common stock, bring the total gross proceeds from the offering to approximately $14,076,000, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Team Nation Holdings Corp Officially Changes its Name; Petr Shares Rise on Brazil Outlook Upgrade
ACCESSWIRE - Thu Mar 27, 11:37PM CDT
Petr (NYSE: PBR) - For an in-depth report on Petr follow: www.BullTrends.com/stockquote/PBR

Nasdaq stocks posting largest volume increases
AP - Thu Mar 27, 5:04PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:

Advaxis Announces Pricing of Public Offering of Common Stock
GlobeNewswire - Wed Mar 26, 7:40PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced the pricing of an underwritten public offering of 4,080,000 shares of common stock at a public offering price of $3.00 per share. The Company expects to receive $12,240,000 in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The Company has granted the underwriters a 45-day option to purchase up to 612,000 additional shares of common stock. The Company intends to use the net proceeds from this offering to fund the Company's continued research and development initiatives in connection with expanding its product line and for other general corporate purposes.

Advaxis Announces Proposed Public Offering of Common Stock
GlobeNewswire - Wed Mar 26, 3:08PM CDT
Advaxis, Inc. (Nasdaq:ADXS) ("Advaxis" or the "Company" , today announced that it intends to offer for sale shares of its common stock in an underwritten public offering. The Company intends to use the net proceeds from this offering to fund the Company's continued research and development initiatives in connection with expanding its product line and for other general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Advaxis, Inc. [ADXS] to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Mar 26, 11:10AM CDT
What:

Advaxis to Ring The NASDAQ Stock Market Closing Bell
GlobeNewswire - Wed Mar 26, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that its management team will ring The NASDAQ Stock Market Closing Bell on Thursday, March 27, 2014.

Advaxis Appoints Sara Bonstein as Chief Financial Officer, Senior Vice President
GlobeNewswire - Mon Mar 24, 4:16PM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has appointed Sara Bonstein to the position of Chief Financial Officer, Senior Vice President. Ms. Bonstein has a decade of financial leadership experience in the life sciences industry with Eli Lilly & Company, ImClone Systems, and Johnson & Johnson.

Advaxis, Inc. "A Win-Win in Pet Therapeutics"
ACCESSWIRE - Fri Mar 21, 8:21AM CDT
Philadelphia, PA / ACCESSWIRE / March 21, 2014 / Advaxis, Inc. (NASDAQ: ADXS) today published a new blog post on The Chairman's Blog, written by the Company's EVP and COO, Mr. Gregory T. Mayes. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

Advaxis Discusses Global Licensing Agreement for Pet Therapeutics on Conference Call
GlobeNewswire - Thu Mar 20, 11:45AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, hosted a joint conference call with Aratana Therapeutics (Nasdaq ETX) today at 8:00 am ET to discuss the recently announced global licensing agreement for Advaxis's ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer.

Aratana and Advaxis Enter Exclusive Global Licensing Agreement
PR Newswire - Wed Mar 19, 7:01PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer. Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing for the treatment of human cancers on a global basis. Under the agreement, Aratana will have exclusive rights to develop and commercialize the licensed immunotherapies for pet health applications, and will focus initially on developing ADXS-cHER2 for osteosarcoma.

Advaxis Receives Patent in Japan for ADXS-HPV for the Treatment of Cervical Cancer
GlobeNewswire - Tue Mar 18, 6:30AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that it has been issued a significant patent from the Japan Patent Office, entitled, "Compositions and Methods for Enhancing Immunogenicity of Antigens". The claims of the patent (patent number 5479918) cover the use of ADXS-HPV for the treatment of late-stage cervical cancer with a term that extends to 2028.

Advaxis and UC San Francisco to Evaluate Cancer Immunotherapy Constructs in Prostate Cancer
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, announced that it has signed an agreement with the University of California, San Francisco (UCSF), under which Lawrence Fong, M.D., Professor in the Department of Medicine and principal investigator of the studies at UCSF, will evaluate several new immunotherapy constructs, in addition to ADXS-PSA, each built on the Advaxis proprietary technology. Data generated from this agreement will demonstrate the combination of the unique Advaxis immunotherapy platform, which generates both tumor fighting T cells and reduces tumor protection inside the tumor microenvironment, with targets that have already been shown to be important in effective immunotherapies for prostate cancer.

Advaxis to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
GlobeNewswire - Thu Mar 13, 8:01AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced that the company will present at the 2 Annual Sachs Cancer Bio Partnering & Investment Forum on Wednesday, March 19 at the New York Academy of Sciences. Robert G. Petit, Ph.D., Chief Scientific Officer of Advaxis, will serve on an expert panel titled "Immunotherapies and Cancer Vaccines" at 11:45am and Daniel J. O'Connor, Chief Executive Officer of Advaxis, will present an update on the Company at 1:30pm.

Biotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, Peregrine
at The Street - Fri Mar 07, 9:49AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 108

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
Neurelis Founder Earns EY's 2026 Top Entrepreneur Honor

Updated Category News Views 95

Some business awards are wallpaper; this one carries real clinical weight. EY US named Craig Chambliss, CEO and co-founder of Neurelis, its Entrepreneur Of The Year 2026 National Overall Award winner. In a sector where plenty of companies talk grandly about changing lives and then vanish into the regulatory fog, the underlying story matters more than the trophy. Neurelis...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 138

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 147

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Epiroc Takes Live Remote Drilling to CES 2027 Stage

Updated Category News Views 48

A drill rig chewing through Virginia rock from a Las Vegas convention booth is either a serious industrial-tech moment or an expensive magic trick. At CES 2027, Epiroc intends to make the distinction painfully clear. From January 6 through 9, the Stockholm-based mining-equipment company and Luck Stone will connect Booth 7031 in the LVCC West Hall to a working quarry in...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 64

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
CVS Puts Youth Soccer Stories on Its Store Shelves

Updated Category News Views 76

Two kids with real community ties just got a megaphone most grown-ups never receive. CVS Pharmacy has named Caroline, 9, of Holmes Beach, Florida, and Zoe, 12, of Los Angeles, as the first grand-prize winners of its Home Team Heroes youth soccer contest. Each player’s selected nonprofit soccer organization will receive a $25,000 grant, while their stories will appear on...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 99

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Triller Lawsuit Puts Merger Disclosures Under a Harsh Light

Updated Category News Views 90

A $0.32 closing price has a way of stripping the paint off a corporate story. The proposed securities class action involving Triller Group, Inc. puts a hard spotlight on a familiar, ugly market sequence: a splashy merger, glowing talk around acquired assets, delayed financial filings, Nasdaq trouble, and then a collapse severe enough to leave shareholders wondering what...

Continue Reading
California Rideshare Data Exposes an Insurance Gap

Updated Category News Views 27

Three California counties carried an outsized share of rideshare traffic, and the insurance fine print is where this story gets uncomfortable. A review by Mendez & Sanchez says Los Angeles, San Francisco, and San Diego counties accounted for nearly two-thirds of statewide rideshare trips between September 2019 and August 2020. That is an old snapshot, sure, but it points...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into Cumberland Heights Data Breach Issue

Updated Category News Views 81

Cumberland Heights Foundation took a hit back in 2024 when Federman & Sherwood launched an investigation into a serious data breach that compromised personal information. The foundation discovered unauthorized access to sensitive data on their Microsoft O365 platform, prompting immediate scrutiny of their security practices. The Breach Unpacked: What Went Down? This...

Continue Reading
The Remarkable Growth of Parker Hannifin Stock Over Two Decades

Updated Category News Views 195

Unveiling Parker Hannifin's 20-Year Growth Journey Parker Hannifin (NYSE: PH) has consistently outperformed market expectations over the past twenty years. This company's remarkable growth story is not just about numbers; it’s a narrative blending innovation, strategy, and resilience. With an average annual return of 15.52%, Parker Hannifin has shown an annualized...

Continue Reading
CoStar Group Earnings Preview: What to Expect This Quarter

Updated Category News Views 174

CoStar Group’s Earnings Report On The Horizon Here we are—a big date looming. CoStar Group (NASDAQ:CSGP) is all set to drop its quarterly earnings report on February 24, 2026. Basically, a lot of eyes are glued to this one. It feels like the calm before the storm, right? Investors want that sweet taste of surpassing estimates, not to mention some favorable guidance...

Continue Reading
Richardson's Strategic Acquisition: Pasta Business Expansion

Updated Category News Views 221

Richardson International Expands with Pasta Acquisition Richardson International Limited, through its US subsidiary Richardson (US) Holdings Limited, has taken a significant step in the food processing sector. The company has entered into a definitive agreement to acquire the pasta business of 8th Avenue Food & Provisions, Inc. This exciting development marks a noteworthy...

Continue Reading
Sandvik Reports Key Financial Metrics for Second Quarter

Updated Category News Views 192

Sandvik's Financial Performance Overview In a recent release, Sandvik Aktiebolag has shared its financial metrics from the second quarter, revealing significant developments in order intake and revenue growth. The company, known for its innovative engineering solutions, reported an order intake of SEK 32,206 million, displaying a slight decline compared to the previous...

Continue Reading